ImmunoGen, Inc.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public, Subsidiary
- Established
- 1981-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.immunogen.com
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-11-09
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 181
- Registration Number
- NCT01237678
- Locations
- ๐บ๐ธ
Johns Hopkins University, Baltimore, Maryland, United States
๐ช๐ธHospital Universitario Virgen del Rocio, Sevilla, Spain
๐ฌ๐งRoyal Marsden, London, London, United Kingdom
IMGN901 in Combination With Lenalidomide and Dexamethasone
- Conditions
- First Posted Date
- 2009-10-08
- Last Posted Date
- 2014-11-21
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00991562
- Locations
- ๐บ๐ธ
Comprehensive Cancer Center of the Desert, Palm Springs, California, United States
๐บ๐ธWeill Medical College, New York, New York, United States
๐บ๐ธRoswell Park Cancer Institute, Buffalo, New York, United States
A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors
- Conditions
- First Posted Date
- 2008-07-24
- Last Posted Date
- 2013-09-13
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00721669
- Locations
- ๐บ๐ธ
Florida Cancer Specialists, Fort Myers, Florida, United States
๐บ๐ธSarah Cannon Research Institute, Nashville, Tennessee, United States
๐บ๐ธUniversity of Oklahoma, Oklahoma City, Oklahoma, United States
huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- ImmunoGen, Inc.
- Registration Number
- NCT00620607
- Locations
- ๐บ๐ธ
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
๐บ๐ธVanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
๐บ๐ธU.T. M.D. Anderson Cancer Center, Houston, Texas, United States
Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors
- Conditions
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2010-03-17
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00352131
- Locations
- ๐บ๐ธ
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
๐บ๐ธUT Health Science Center, San Antonio, Texas, United States
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
- Conditions
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2015-03-26
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT00346385
- Locations
- ๐บ๐ธ
University of California San Francisco, San Francisco, California, United States
๐บ๐ธOklahoma University, Oklahoma City, Oklahoma, United States
๐บ๐ธM. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2013-04-23
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT00346255
- Locations
- ๐ฆ๐ท
Juan Domingo Peron 1500 - (B1629AHJ) Pilar, Buenos Aires, Argentina
๐บ๐ธSt. Vincent's Comprehensive Cancer Center - Manhattan, New York, New York, United States
๐บ๐ธRoswell Park Cancer Institute, Buffalo, New York, United States
Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer
- First Posted Date
- 2003-07-24
- Last Posted Date
- 2012-07-18
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT00065429
- Locations
- ๐บ๐ธ
Greater Dayton Cancer Center, Kettering, Ohio, United States
๐บ๐ธThe Ohio State University, Colombus, Ohio, United States
๐บ๐ธBaystate Medical Center, Springfield, Massachusetts, United States